We are live on
!
Find out more
AVM
Arch Venture Management Portfolio holdings
AUM
$677M
1-Year Est. Return
322.07%
This Fund
S&P 500
This Quarter
Est. Return
-3.99%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76.7M
AUM Growth
-$14.6M
(-16%)
Cap. Flow
-$5.69M
Cap. Flow
% of AUM
-7.42%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IOTS
Adesto Technologies Corp
IOTS
|
+$16.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fate Therapeutics
FATE
|
+$11.1M |
| 2 |
Kura Oncology
KURA
|
+$7.41M |
| 3 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
+$3.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.27% |
| 2 | Technology | 22.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RUBY
1
DELISTED
Rubius Therapeutics, Inc
RUBY
| $24.9M | 32.42% |
2,618,351
| – | – |
|
|
SYRS
2
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $22.9M | 29.84% |
331,382
-54,123
| -14% | -$3.28M |
|
|
IOTS
3
DELISTED
Adesto Technologies Corp
IOTS
| $17.4M | 22.73% |
+2,051,511
| New | +$16.1M |
|
|
CHMA
4
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $5.94M | 7.74% |
1,196,776
| – | – |
|
|
5
Kura Oncology
KURA
$916M
| $5.59M | 7.28% |
406,307
-500,000
| -55% | -$7.41M |
|
|
6
Fate Therapeutics
FATE
$290M
| – | – |
-716,392
| Closed | -$11.1M |
|
Similar funds
NI
MMPW
JC
NCM
TWM
DLIC
REAM
MCO
Arch Venture Management's Q4 2019 Portfolio in Review
As of Q4 2019, Arch Venture Management held 6 positions worth $76.7M, down 16% from $91.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Arch Venture Management withdrew a net $5.69M in Q4 2019, closing 1 position and reducing 2 holdings. Its most notable exit was Fate Therapeutics, an estimated $11.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 100% a quarter earlier, followed by Technology.
Against the trend, Arch Venture Management opened a new position in Adesto Technologies Corp worth $17.4M.
- Arch Venture Management's largest Q4 2019 buy was Adesto Technologies Corp: 2,051,511 shares worth $17.4M.
- Arch Venture Management's biggest Q4 2019 reduction was Kura Oncology, cutting an estimated $7.41M.
- Arch Venture Management fully exited Fate Therapeutics in Q4 2019, selling an estimated $11.1M.
- Arch Venture Management's ten largest holdings make up 100% of its $76.7M portfolio in Q4 2019.
- Arch Venture Management opened 1 new position and closed 1 in Q4 2019.
- Arch Venture Management's portfolio value fell 16% quarter-over-quarter to $76.7M.
Based on Arch Venture Management's 13F filing for Q4 2019, filed 5 Feb 2020.